 SALT LAKE CITY, Aug. 13, 2021 PRNewswire -- Recursion Nasdaq: RXRX, a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results and business updates for its second quarter ending June 30, 2021. We are excited with how Recursion is expanding across many fronts in order to deliver on our mission to decode biology to radically improve lives, said Recursion Co-Founder CEO Chris Gibson, PhD. 